Consultants Laboratory of Wisconsin, LLC
Consultants Laboratory of Wisconsin, LLC was paid $4.64M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 18% of everything it billed.
FOND DU LAC, WI 54935
Next to other Clinical Medical Laboratory providers in Wisconsin
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,604 | $579K | |
| 2019 | 43,489 | $528K | |
| 2020 | 46,062 | $570K | |
| 2021 | 66,421 | $1.03M | |
| 2022 | 60,741 | $888K | |
| 2023 | 55,765 | $572K | |
| 2024incomplete | 47,311 | $477K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 13,895 | 9,980 | $814K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.1% | 7,355 | 6,741 | $235K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.9% | 7,280 | 6,681 | $229K |
| 80050 | General health panel | 4.7% | 4,982 | 4,506 | $216K |
| 80053 | Comprehensive metabolic panel | 4.1% | 22,152 | 19,171 | $190K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.8% | 7,084 | 6,487 | $175K |
| 80061 | Lipid panel | 3.4% | 13,463 | 12,526 | $159K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.2% | 1,166 | 1,071 | $150K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.2% | 9,926 | 7,377 | $149K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 23,347 | 19,277 | $148K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 10,309 | 9,414 | $148K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 3.1% | 5,758 | 5,329 | $145K |
109 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 2.8% | 9,438 | $130K |
| 80081 | 2.5% | 1,710 | $117K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.1% | 12,314 | $98K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 1,129 | $84K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 650 | $81K |
| 87800 | 1.6% | 3,336 | $72K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.5% | 2,378 | $72K |
| 87081 | 1.4% | 9,850 | $63K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 8,380 | $58K |
| 87653 | 1.2% | 1,670 | $56K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 2,536 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 8,224 | $54K |
| 82607 | <1% | 3,590 | $46K | |
| 86803 | <1% | 3,181 | $40K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,923 | $40K |
| 82728 | <1% | 3,679 | $39K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,231 | $36K |
| 87077 | <1% | 5,160 | $36K | |
| 81001 | <1% | 12,420 | $35K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 837 | $33K |
| 84153 | <1% | 1,775 | $29K | |
| 85027 | <1% | 4,883 | $28K | |
| 87186 | <1% | 3,938 | $28K | |
| 84702 | <1% | 2,311 | $26K | |
| 83970 | <1% | 932 | $25K | |
| 81025 | <1% | 3,319 | $25K | |
| 80306 | <1% | 1,739 | $24K | |
| 84466 | <1% | 2,486 | $24K | |
| 83880 | <1% | 809 | $22K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 615 | $22K |
| 87070 | <1% | 2,864 | $22K | |
| 83655 | <1% | 2,266 | $21K | |
| 84439 | <1% | 2,629 | $20K | |
| 83735 | <1% | 3,684 | $20K | |
| 82043 | <1% | 4,209 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 616 | $19K |
| 85610 | <1% | 5,422 | $18K | |
| 83540 | <1% | 3,382 | $17K | |
| 82746 | <1% | 1,297 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 408 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 51,551 | $13K |
| 86140 | <1% | 2,772 | $12K | |
| 87632 | <1% | 55 | $12K | |
| 82570 | <1% | 2,495 | $11K | |
| 87631 | <1% | 87 | $10K | |
| 85652 | <1% | 3,744 | $9K | |
| 82274 | <1% | 621 | $9K | |
| 82950 | <1% | 1,753 | $8K | |
| 84481 | <1% | 555 | $7K | |
| 84703 | <1% | 959 | $7K | |
| 81003 | <1% | 3,805 | $7K | |
| 80076 | <1% | 937 | $7K | |
| 87340 | <1% | 672 | $6K | |
| 83690 | <1% | 972 | $6K | |
| 85018 | <1% | 2,319 | $5K | |
| 82565 | <1% | 1,321 | $5K | |
| 87493 | <1% | 129 | $4K | |
| 86592 | <1% | 1,038 | $4K | |
| 82248 | <1% | 726 | $3K | |
| 84460 | <1% | 687 | $3K | |
| 84403 | <1% | 118 | $2K | |
| 87205 | <1% | 641 | $2K | |
| 80069 | <1% | 361 | $2K | |
| 87210 | <1% | 449 | $2K | |
| 87427 | <1% | 170 | $2K | |
| 86038 | <1% | 174 | $2K | |
| 86780 | <1% | 198 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 67 | $2K |
| 36416 | <1% | 1,300 | $2K | |
| 86762 | <1% | 138 | $2K | |
| 87088 | <1% | 291 | $2K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,096 | $2K |
| 84100 | <1% | 469 | $2K | |
| 87045 | <1% | 115 | $1K | |
| 82247 | <1% | 259 | $1K | |
| 84550 | <1% | 359 | $1K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,261 | $1K |
| 88142 | <1% | 57 | $1K | |
| 83001 | <1% | 70 | $1K | |
| 82784 | <1% | 136 | $1K | |
| 83516 | <1% | 183 | $990.53 | |
| 86481 | <1% | 13 | $929.00 | |
| 84450 | <1% | 173 | $861.94 | |
| 86850 | <1% | 210 | $806.19 | |
| 80164 | <1% | 62 | $805.80 | |
| 86364 | <1% | 78 | $755.73 | |
| 87046 | <1% | 228 | $704.54 | |
| 85379 | <1% | 92 | $702.21 | |
| 80074 | <1% | 14 | $653.18 | |
| 87338 | <1% | 58 | $627.92 | |
| 85014 | <1% | 188 | $532.28 | |
| 84156 | <1% | 167 | $524.36 | |
| 84144 | <1% | 30 | $490.02 | |
| 86900 | <1% | 188 | $436.04 | |
| 82947 | <1% | 101 | $417.50 | |
| 85007 | <1% | 214 | $410.08 | |
| 86901 | <1% | 165 | $390.11 | |
| 86431 | <1% | 67 | $351.04 | |
| 87230 | <1% | 25 | $347.84 | |
| 86703 | <1% | 27 | $314.25 | |
| 84146 | <1% | 13 | $238.38 | |
| 83993 | <1% | 12 | $235.56 | |
| 82150 | <1% | 30 | $232.84 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 1,122 | $222.01 |
| 82533 | <1% | 15 | $158.36 | |
| 86706 | <1% | 12 | $128.87 | |
| 80178 | <1% | 16 | $82.30 | |
| 82550 | <1% | 14 | $73.06 | |
| 87015 | <1% | 12 | $51.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Consultants Laboratory of Wisconsin, LLC | Mayville, WI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.